Relmada Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Relmada Therapeutics (RLMD).

Price Target Range — 6 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Sell

Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+174.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 18, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$12
Mar 24, 2026	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$12
Mar 20, 2026	Mizuho	Uy Ear	PT Raise	Outperform	$10→$19
Mar 2, 2026	LUCID CAPITAL MARKETS	Christopher Liu	Initiate	Buy	$14
Jan 23, 2026	Leerink Partners	Andrew Berens	Upgrade	Market Perform→Outperform	$8
Dec 22, 2025	Jefferies	Farzin Haque	Initiate	Buy	$9
Nov 19, 2025	Mizuho	Uy Ear	Upgrade	Neutral→Outperform	$1→$10
Dec 5, 2024	Mizuho	Uy Ear	Downgrade	Outperform→Neutral	$23→$1
Dec 4, 2024	Leerink Partners	Marc Goodman	Downgrade	Outperform→Market Perform	$10→$1
Sep 17, 2024	Jefferies	Andrew Tsai	Upgrade	Hold→Buy	$4→$13
Jun 5, 2024	Goldman Sachs	Andrea Tan	Downgrade	Neutral→Sell	$3→$2

Analyst Ratings News

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.

Vandana Singh

This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG.

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.

Benzinga Newsdesk

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $14.

Benzinga Newsdesk

Relmada Therapeutics Inc

Relmada Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

PRO
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14

People Also Watch

People Also Watch

Relmada Therapeutics Inc

Relmada Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROHC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

PROPiper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

PROMizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

PROLUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

PRO
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14